You are here

ACS Med Chem Lett DOI:10.1021/ml300172p

Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies.

Publication TypeJournal Article
Year of Publication2012
AuthorsDockendorff, C, Nagiec, MM, Weïwer, M, Buhrlage, S, Ting, A, Nag, PP, Germain, A, Kim, H-J, Youngsaye, W, Scherer, C, Bennion, M, Xue, L, Stanton, BZ, Lewis, TA, MacPherson, L, Palmer, M, Foley, MA, Perez, JR, Schreiber, SL
JournalACS Med Chem Lett
Date Published2012 Oct 11

Macrocyclic Hedgehog (Hh) pathway inhibitors have been discovered with improved potency and maximal inhibition relative to the previously reported macrocycle robotnikinin. Analogues were prepared using a modular and efficient build-couple-pair (BCP) approach, with a ring-closing metathesis step to form the macrocyclic ring. Varying the position of the macrocycle nitrogen and oxygen atoms provided inhibitors with improved activity in cellular assays; the most potent analogue was 29 (BRD-6851), with an IC(50) of 0.4 μM against C3H10T1/2 cells undergoing Hh-induced activation, as measured by Gli1 transcription and alkaline phosphatase induction. Studies with Patched knockout (Ptch(-/-)) cells and competition studies with the Smoothened (Smo) agonists SAG and purmorphamine demonstrate that in contrast to robotnikinin, select analogues are Smo antagonists.


Alternate JournalACS Med Chem Lett
PubMed ID23074541
PubMed Central IDPMC3469069
Grant ListR01 GM038627 / GM / NIGMS NIH HHS / United States